Subscribe to RSS
DOI: 10.1055/s-0042-104658
Pharmacokinetics of Compound D, the Major Bioactive Component of Zingiber cassumunar, in Rats
Publication History
received 26 April 2015
revised 29 February 2016
accepted 02 March 2016
Publication Date:
28 April 2016 (online)
Abstract
Rhizomes of Zingiber cassumunar have been used for many years in traditional Thai medicine as an anti-inflammatory agent. The major bioactive component of this plant is Compound D [E-4-(3′, 4′-dimethoxyphenyl)but-3-en-1-ol], which is a strong smooth muscle relaxant, and has antihistamine and anti-inflammatory actions. There is, however, incomplete information available for the pharmacokinetics of Compound D in mammals. In this study, we examined the pharmacokinetic profiles of Compound D in male Wistar rats. A standardized extract of Z. cassumunar containing 4 % w/w Compound D was administered intravenously at 25 mg/kg or by oral gavage at 25, 75, or 250 mg/kg to Wistar rats. Blood, tissues, urine, and feces were collected from 0 to 48 h after dosing and the level of Compound D was determined by liquid chromatography-tandem mass spectrometry. The concentration of Compound D ranged from 10–100 µg/L, reached a maximum approximately 0.15 h after oral dosing. Compound D exhibited an excellent tissue to plasma ratio, ranging from 1- to 1000 in several organs at 1–4 h after oral dosing. Less than 1 % of unchanged Compound D was excreted in the urine and feces. Further studies on tissue uptake and metabolite identification are required to obtain complete pharmacokinetic information and to develop appropriate dosing strategies of Compound D and the standardized extract of Z. cassumunar.
-
References
- 1 Farnsworth NR, Bunyapraphatsara N. Thai medicinal plants recommended for primary health care system. Bangkok: Medicinal Plants Information Center, Faculty of Pharmacy, Mahidol University; 1992
- 2 Tuchinda M, Srimaruta N, Habanananda P, Kanchanapee P, Dechatiwongse T. Study of Plai (Zingiber cassumunar Roxb.) in asthmatic children. Siriraj Hosp Gaz 1984; 36: 1-5
- 3 Youngchiyud P, Wasi P, Suthamsmi T, Kanchanapee P, Dechatiwonge T. Clinical assessment of the efficacy and tolerance of Zingiber cassumunar Roxb. Siriraj Hosp Gaz 1985; 37: 435-440
- 4 Jeenapongsa R, Yoovathaworn K, Sriwatanakul KM, Pongprayoon U, Sriwatanakul K. Anti-inflammatory activity of (E)-1-(3, 4-dimethoxyphenyl) butadiene from Zingiber cassumunar Roxb. J Ethnopharmacol 2003; 87: 143-148
- 5 Ozaki Y, Kawahara N, Harada M. Anti-inflammatory effect of Zingiber cassumunar Roxb. and its active principles. Chem Pharm Bull (Tokyo) 1991; 39: 2353-2356
- 6 Pongprayoon U, Soontornsaratune P, Jarikasem S, Sematong T, Wasuwat S, Claeson P. Topical antiinflammatory activity of the major lipophilic constituents of the rhizome of Zingiber cassumunar. Part I: The essential oil. Phytomedicine 1997; 3: 319-322
- 7 Pongprayoon U, Tuchinda P, Claeson P, Sematong T, Reutrakul V, Soontornsaratune P. Topical antiinflammatory activity of the major lipophilic constituents of the rhizome of Zingiber cassumunar. Part II: Hexane extractives. Phytomedicine 1997; 3: 323-326
- 8 Kanjanapothi D, Soparat P, Panthong A, Tuntiwachwuttikul P, Reutrakul V. A uterine relaxant compound from Zingiber cassumunar . Planta Med 1987; 53: 329-332
- 9 Kiatyingungsulee N, Wangmad M, Sawadimongkol D, Mokkamit M. [Some pharmacological studies of active constituent in Plai]. Bull Dept Med Sci 1979; 21: 13-25
- 10 Pubchem Compound Website. Available at. https://pubchem.ncbi.nlm.nih.gov/compound/6439118%23section=Substance-Categorization-Classification Accessed June 1, 2015
- 11 Koysooko R, Worawattanakul M, Pinthong T. [Pharmacokinetic studies of bronchodilating active constituent from Plai]. Bull Dept Med Sci 1986; 28: 65-73
- 12 Koysooko R, Varavudhi P, Pinthong T, Wattanapermpool J. Development of Zingiber cassumunar for asthmatic treatment: pharmacokinetics in animals. J Sci Soc Thailand 1988; 14: 197-208
- 13 Panthong A, Kanjanapothi D, Niwatananant W, Tuntiwachwuttikul P, Reutrakul V. Anti-inflammatory activity of compound D {(E)-4-(3′,4′-dimethoxyphenyl)but-3-en-2-ol} isolated from Zingiber cassumunar Roxb. Phytomedicine 1997; 4: 207-212
- 14 Han AR, Kim MS, Jeong YH, Lee SK, Seo EK. Cyclooxygenase-2 inhibitory phenylbutenoids from the rhizomes of Zingiber cassumunar . Chem Pharm Bull 2005; 53: 1466-1468
- 15 Chaiwongsa R, Ongchai S, Boonsing P, Kongtawelert P, Panthong A, Reutrakul V. Active compound of Zingiber cassumunar Roxb. down-regulates the expression of genes involved in joint erosion in a human synovial fibroblast cell line. Afr J Tradit Complement Altern Med 2013; 10: 40-48
- 16 Department of Medical Sciences. Ministry of Public Health. Thai Herbal Pharmacopoeia. Bangkok, Thailand: Prachachon Co., Ltd.; 1995
- 17 Koontongkaew S, Meesuk L, Aupaphong V, Ayudhaya T, Poachanukoon O. Inhibitory effect of Zingiber cassumunar extracts on lipopolysaccharide‐induced cyclooxygenase‐2 and matrix metalloproteinase expression in human gingival fibroblasts. J Periodontal Res 2013; 48: 507-516
- 18 U.S. Food and Drug Administration. Guidance for industry. Bioanalytical method validation; 2001. Available at. http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf Accessed June 1, 2015